Lycorine weakens tamoxifen resistance of breast cancer via abrogating HAGLR ‐mediated epigenetic suppression on VGLL4 by DNMT1
The Kaohsiung Journal of Medical Sciences · 2023
DOI: 10.1002/kjm2.12636 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2023. Verfasst von Jing Zhai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Gansu provincial Hospital, Lanzhou, Gansu Province, People's Republic of China. Hauptthemen laut MEDLINE: Breast Neoplasms, Tamoxifen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Much is known about the significance of lycorine, a natural alkaloid, in combating various types of cancer, including breast cancer (BC), but whether it participates in regulating tamoxifen (TAM) resistance and its underlying mechanism remain to be elucidated. Tamoxifen‐resistant (TAMR) BC cells were first established by continuously exposed to increasing concentrations of TAM. Levels of targeted gene including HOXD antisense growth‐associated lncRNA (HAGLR) and Vestigial like family member 4 (VGLL4) were analyzed by qRT‐PCR and western blot, respectively. Cell proliferation ability was assessed by MTT and EdU assays. Flow cytometry was carried out to evaluate the apoptosis. VGLL4 promoter methylation was examined using methylation specific PCR (MSP). The role of HAGLR acting on the expression of VGLL4 via DNA hypermethylation was confirmed by RNA immunoprecipitation (RIP). Here, we reported that lycorine administration reduced the survival ratio of TAMR BC cells, decreased the IC 50 of TAM, and strengthened TAM‐induced apoptosis. HAGLR, observed to be highly expressed in TAMR BC cells, was identified to be a downstream effector of lycorine, of which overexpression abolished lycorine‐mediated TAMR inhibition. VGLL4 served as a target of HAGLR in regulating lycorine‐mediated suppression on tamoxifen resistance of TAMR BC cells. Mechanistically, HAGLR epigenetically suppressed VGLL4 expression via DNA methyltransferase 1 (DNMT1)‐mediated DNA hypermethylation. Taken together, our data highlights the pivotal role of lycorine in TAM resistance of BC, which may provide a potential agent for improving the effectiveness and efficacy of BC resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Gansu provincial Hospital, Lanzhou, Gansu Province, People's Republic of China.
- Division of Oncology, Gansu Provincial Cancer Hospital, Lanzhou, Gansu Province, People's Republic of China.
ORCID-Profile: Lei Shi
Zitieren
APA
Zhai, J., Jiang, J. F., & Shi, L. (2023). Lycorine weakens tamoxifen resistance of breast cancer via abrogating HAGLR ‐mediated epigenetic suppression on VGLL4 by DNMT1. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.12636
Vancouver
Zhai J, Jiang JF, Shi L. Lycorine weakens tamoxifen resistance of breast cancer via abrogating HAGLR ‐mediated epigenetic suppression on VGLL4 by DNMT1. The Kaohsiung Journal of Medical Sciences. 2023. doi:10.1002/kjm2.12636
BibTeX
@article{Zhai2023,
author = {Zhai, Jing and Jiang, Jun-Feng and Shi, Lei},
title = {Lycorine weakens tamoxifen resistance of breast cancer via abrogating HAGLR ‐mediated epigenetic suppression on VGLL4 by DNMT1},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2023},
doi = {10.1002/kjm2.12636}
}
EUVIMED